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Introduction {#sec007}
============

Depressive disorders were the third largest cause of adolescent disability-adjusted life years lost globally in 2015 \[[@pmed.1003215.ref001]\]. Compared with adults, children and young people (CYP) with major depressive disorder are still underdiagnosed and undertreated \[[@pmed.1003215.ref002],[@pmed.1003215.ref003]\]. Consequences of depressive episodes in young people include serious impairments in social functioning and school performance, as well as suicidal ideation and attempts \[[@pmed.1003215.ref004]\]. Psychological treatments are still considered the first-line treatment in many clinical guidelines, including the UK National Institute for Health and Care Excellence (NICE) guidelines for depression in CYP \[[@pmed.1003215.ref005]\]. However, 22.7% of CYP with emotional disorders reported waiting more than 6 months to see a mental health specialist in England in 2017 \[[@pmed.1003215.ref006]\], and antidepressants are widely used in the treatment of depression in children and adolescents.

The efficacy and safety of antidepressant medicines for major depression in CYP remains controversial \[[@pmed.1003215.ref007]\]. Fluoxetine is the only antidepressant licensed for use in CYP as a first-line treatment for major depression in the UK \[[@pmed.1003215.ref008]\] and the US \[[@pmed.1003215.ref009]\]. In the UK, other antidepressants are licensed for obsessive-compulsive disorder (fluvoxamine and sertraline) and nocturnal enuresis (imipramine), and these drugs are recommended as the first antidepressants to use by the relevant NICE guidelines \[[@pmed.1003215.ref010],[@pmed.1003215.ref011]\]. Amitriptyline has neuropathic pain listed as an unlicensed indication in the British National Formulary for Children \[[@pmed.1003215.ref008]\] and is suggested as a prophylactic treatment for migraines in NICE guidelines on headaches in over-12s \[[@pmed.1003215.ref012]\]. Tricyclic antidepressants, in particular imipramine, have historically been used as a second or third line drug in the management of attention-deficit hyperactivity disorder (ADHD) in children despite being unlicensed for this indication \[[@pmed.1003215.ref008]\]. Therefore, examining the trends in antidepressants prescribed to CYP may indicate changes in relation to the indications these drugs are licensed for, as well as whether NICE guidelines and evidence-based practice are being followed. According to NICE guidelines, in the UK, prescribing antidepressants to CYP should only be done after assessment and diagnosis by a child and adolescent psychiatrist \[[@pmed.1003215.ref005],[@pmed.1003215.ref010]\] or other specialist with expertise in child and adolescent mental health \[[@pmed.1003215.ref011]\]. Referral to specialists in secondary care would usually be made, when appropriate, after visiting a general practitioner (GP) in primary care \[[@pmed.1003215.ref013]\]. Work examining indications recorded in primary care around the time of the first antidepressant prescription and which secondary care specialists were seen has been done separately \[[@pmed.1003215.ref014]\].

Antidepressant prescriptions for young people were increasing until a drop in 2002, and then began significantly increasing again from 2005 both in the UK \[[@pmed.1003215.ref015]--[@pmed.1003215.ref019]\] and other countries \[[@pmed.1003215.ref020]--[@pmed.1003215.ref023]\]. Increased prescribing of antidepressants could indicate a greater awareness and recognition of mental health and related issues and a willingness to seek help in the form of being diagnosed and/or treated. There is some evidence that in people of all ages, antidepressant prescribing varies by region \[[@pmed.1003215.ref024]\] and between different ethnic groups in England \[[@pmed.1003215.ref025],[@pmed.1003215.ref026]\]. Previous studies showing that CYP living in more deprived areas are more likely to receive antidepressant prescriptions have not taken region or ethnicity into account \[[@pmed.1003215.ref015],[@pmed.1003215.ref016]\]. There is generally a lack of evidence about variation in antidepressant prescribing in CYP, particularly taking other possibly confounding factors into account. Differences in prescribing by deprivation, geographical location, and ethnicity could indicate differences in the distribution of risk factors for mental health disorders and/or differences in access to psychological therapies, which could both affect the likelihood of antidepressant prescribing.

It remains unclear, based on previous studies, whether the reported rise in antidepressant prescribing in CYP that began in 2005 is continuing and whether there is variation in prescribing across different groups. Our study aimed to examine changes over time and the variation in the use of antidepressant medicines in CYP aged between 5 and 17 years old between 1998 and 2017 in England. Our objectives were to 1) describe differences in antidepressant prescriptions for CYP over time by age, sex, deprivation, region, and ethnicity; 2) estimate variation in prescribing between these groups adjusting for the other factors; and 3) assess to what extent NICE guidelines for CYP are being adhered to.

Methods {#sec008}
=======

The full protocol for the study has previously been published \[[@pmed.1003215.ref027]\]. Any analyses that were not prespecified in the protocol are described as sensitivity or post hoc analyses below. This study is reported as per the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guideline (see [S1 STROBE Checklist](#pmed.1003215.s001){ref-type="supplementary-material"}).

Data sources {#sec009}
------------

The cohort was extracted from a large primary care database (QResearch, version 43) linked to hospital episode statistics (HES) admitted patient care and outpatient data. At the time of the study, the QResearch database included health records of over 32 million patients from more than 1,500 general practices across the UK that record data using the Egton Medical Information Systems (EMIS) medical records computer system.

Study participants {#sec010}
------------------

The study's open cohort was defined as all people registered on the QResearch database in England who were aged between 5 and 17 years between 1 January 1998 and 31 December 2017. Each person's study entry date was defined as the latest date of the following: 12 months after their registration with a study practice, 12 months after the installation date of their practice's EMIS computer system, 1 January of the year they turned 5 years old, or 1 January 1998. People were then followed up until the earliest date of them leaving the practice, dying, 1 January of the year they turned 18 years old, or the end of the follow-up period (31 December 2017).

Outcomes {#sec011}
--------

We extracted information on prescriptions for any antidepressant for each person in the cohort. In some cases, we had prescribing information from before a patient registered with a practice because of electronic transferring of prescription data or before the practice installed EMIS. In this way, we could identify prescriptions that took place before the study period. We examined all antidepressants combined and 4 different drug classes: selective serotonin reuptake inhibitors (SSRIs), tricyclic and related antidepressants (TCAs), serotonin and norepinephrine reuptake inhibitors (SNRIs), and other antidepressants, including monoamine oxidase inhibitors (MAOIs). Antidepressants included in each drug class can be found in [S1 Table](#pmed.1003215.s002){ref-type="supplementary-material"}. We also considered individual antidepressant drugs separately. For the figures, the 10 most prescribed antidepressants overall (each representing at least 0.8% of prescriptions) were included. Any antidepressant prescribed within the study period was included in the prevalence analyses. Those with a record of an antidepressant prescription before their study entry were excluded for the incidence cohort so that only the first antidepressant prescription was examined.

Covariates {#sec012}
----------

We analysed 4 groups, defined by sex (female and male) and age (5--11 and 12--17 years). These age groups are similar to those specified in the NICE guidelines on depression in CYP \[[@pmed.1003215.ref005]\] but exclude 18-year-olds, who may have been treated as adults. We also studied trends and variation for deprivation, different regions of England, and ethnic groups. Deprivation was measured using the Townsend deprivation index, an area-based measure of deprivation that combines information on 4 indicators (unemployment, non-car ownership, non-home ownership, household overcrowding) from the census \[[@pmed.1003215.ref028]\]. Areas are then divided into quintiles based on their score. When ethnicity information was missing in QResearch, we supplemented this with the most recent valid ethnic code available in HES. We examined 5 broad ethnic groups: White, Mixed, Asian, Black, and Chinese or other ethnic group, plus those with no recorded ethnicity.

Statistical analysis {#sec013}
--------------------

We calculated incidence rates for being first prescribed an antidepressant and prevalence rates for people with a first or subsequent antidepressant prescription per 1,000 person-years for each year between 1998 and 2017. These were produced for the different sex and age groups for all antidepressants, the drug classes, and individual drugs as described above.

Incidence rate ratios were calculated using multilevel mixed-effects Poisson regression to take account of any clustering within GP practices for the different sex and age groups. The fully adjusted models included year, region, Townsend deprivation quintile, and ethnic group. In order to take account of varying patterns in antidepressant prescribing over time, linear trends were assessed for different periods using piecewise linear regression \[[@pmed.1003215.ref029]\] with change points identified by previous studies: 2002 and 2005 \[[@pmed.1003215.ref015],[@pmed.1003215.ref017]\]. The year 2008 was also identified as a change point for antidepressant prevalence in people aged 14 years and over, but not incidence \[[@pmed.1003215.ref017]\]. We included this and assessed its statistical significance because our study has a longer follow-up than the previous analysis. Sensitivity analyses recoding the not known ethnic group to White and examining prescribing by deprivation after excluding London data were also performed after examining the initial results.

As a post hoc analysis, we assessed whether the incidence rate ratios (IRRs) for 12- to 17-year-olds from the Poisson regression were linked to other factors in each region. For this, we plotted the IRRs alongside previously published data from other sources: local authority spending on 'low-level' mental health services (those that are nonspecialist, preventive, and early intervention, which fall below specialist referral thresholds) per child in the 2018--2019 financial year in regions in England \[[@pmed.1003215.ref030]\] and prevalence estimates of any depressive disorder and any anxiety disorder for each region from a national survey in England in 2017 of CYP aged 5--19 years \[[@pmed.1003215.ref006]\].

All analyses were performed using Stata/SE v15 (StataCorp LLC, TX, USA).

Ethics statement {#sec014}
----------------

The project was independently peer reviewed and accepted by the QResearch Scientific board and approved in accordance with the procedure agreed with the Trent Research Ethics Committee (reference: 18/EM/0400).

Results {#sec015}
=======

The flow chart detailing the selection of the cohort is shown in [Fig 1](#pmed.1003215.g001){ref-type="fig"}. There were 4,349,638 CYP included in the prevalence study cohort. Of these, 14,537 (0.3%) had their first antidepressant prescription before their study entry date and were excluded from the incidence cohort. This left 49,434 CYP who were first prescribed an antidepressant during the study period. Details of characteristics of the incidence cohort and the subcohort prescribed their first antidepressant are shown in [Table 1](#pmed.1003215.t001){ref-type="table"}. Almost three-quarters of the incidence cohort (nearly 3.2 million participants) entered the study aged between 5 to 11 years, and the median follow-up time was 3.6 years (interquartile range: 1.5--7.2 years). Ethnicity information was available in QResearch for 2,317,010 (53.5%) of the incidence cohort and was supplemented by HES records for a further 307,810 (7.1%).

![Flowchart of selection of study participants.](pmed.1003215.g001){#pmed.1003215.g001}

10.1371/journal.pmed.1003215.t001

###### Characteristics of incidence cohort (incidence cohort excludes 14,537 patients with first antidepressant prescription before study entry) and the subset with a new prescription of any antidepressant during the study period, age 5 to 17 years, England 1998--2017.

![](pmed.1003215.t001){#pmed.1003215.t001g}

                                             Incidence Cohort     Any New Antidepressant Prescribed Subcohort                     
  ------------------------------------------ -------------------- --------------------------------------------- -------- -------- -------
                                             n                    \%                                            n        \%       
  Total                                                           4,335,101                                     100%     49,434   100%
  Age[\*](#t001fn001){ref-type="table-fn"}   5--11 years          11.4 m person-years                           5,133    10.4%    
  12--17 years                               9.0 m person-years   44,301                                        89.6%             
  Sex                                        Female               2,080,843                                     48.0%    32,571   65.9%
  Male                                       2,254,258            52.0%                                         16,863   34.1%    
  Townsend deprivation quintile              1 (least deprived)   973,529                                       22.5%    11,943   24.2%
  2                                          923,863              21.3%                                         12,066   24.4%    
  3                                          863,260              19.9%                                         10,856   22.0%    
  4                                          800,643              18.5%                                         8,778    17.8%    
  5 (most deprived)                          761,722              17.6%                                         5,687    11.5%    
  Not known                                  12,079               0.3%                                          104      0.2%     
  Region                                     East Midlands        206,792                                       4.8%     2,816    5.7%
  East of England                            252,108              5.8%                                          3,807    7.7%     
  London                                     1,056,707            24.4%                                         5,723    11.6%    
  North East                                 148,885              3.4%                                          1,943    3.9%     
  North West                                 672,537              15.5%                                         7,973    16.1%    
  South East                                 887,291              20.5%                                         13,261   26.8%    
  South West                                 430,169              9.9%                                          5,866    11.9%    
  West Midlands                              474,983              11.0%                                         5,464    11.1%    
  Yorkshire & Humber                         205,629              4.7%                                          2,581    5.2%     
  Ethnicity                                  Not known            1,710,263                                     39.5%    15,853   32.1%
  Known                                      2,624,838            60.5%                                         33,581   67.9%    
  Ethnic group (% of known)                  White                1,975,726                                     75.3%    30,731   91.5%
  Mixed                                      86,678               3.3%                                          566      1.7%     
  Asian                                      302,499              11.5%                                         1,419    4.2%     
  Black                                      185,606              7.1%                                          562      1.7%     
  Chinese/Other                              74,329               2.8%                                          303      0.9%     

\*Number of person-years included given for incidence cohort by age, as some people were included in both age groups over the study period

Overall, SSRIs (62.6%) were the most commonly prescribed first antidepressant, followed by TCAs (35.7%) ([Table 2](#pmed.1003215.t002){ref-type="table"}). SNRIs (0.5%) and other antidepressants (1.3%) were rarely prescribed as the first antidepressant. The 5 most commonly prescribed first antidepressants were all either licensed for use in CYP (fluoxetine, imipramine, and sertraline) or mentioned in NICE guidelines (amitriptyline and citalopram, although citalopram is only recommended as a second-line antidepressant in the treatment of depression). Over a third of first prescriptions were fluoxetine, a quarter were amitriptyline, and there were similar proportions of citalopram (11.8%) and sertraline (11.4%) prescriptions. Despite being licensed for treating obsessive-compulsive disorder in CYP, fluvoxamine was rarely prescribed as a first antidepressant in the study period, making up only 0.1% of new prescriptions.

10.1371/journal.pmed.1003215.t002

###### Number and percentage of CYP with first prescriptions in each drug class and for individual drugs during the study period, England 1998--2017, by age and sex.

![](pmed.1003215.t002){#pmed.1003215.t002g}

                       Total            5--11 Years   12--17 Years                                              
  -------------------- -------- ------- ------------- -------------- ------- -------- -------- ------- -------- -------
  Any antidepressant   49,434   100%    1,845         100%           3,288   100%     30,726   100%    13,575   100%
  Drug class                                                                                                    
  SSRI                 30,949   62.6%   298           16.2%          594     18.1%    20,895   68.0%   9,162    67.5%
  TCA                  17,624   35.7%   1,538         83.4%          2,674   81.3%    9,285    30.2%   4,127    30.4%
  SNRI                 263      0.5%    6             0.3%           11      0.3%     161      0.5%    85       0.6%
  Other                640      1.3%    \<5           \<0.3%         9       0.3%     414      1.3%    214      1.6%
  Individual drug                                                                                               
  Fluoxetine           17,493   35.4%   171           9.3%           335     10.2%    11,940   38.9%   5,047    37.2%
  Amitriptyline        12,181   24.6%   709           38.4%          921     28.0%    7,627    24.8%   2,924    21.5%
  Citalopram           5,828    11.8%   29            1.6%           43      1.3%     4,244    13.8%   1,512    11.1%
  Sertraline           5,612    11.4%   83            4.5%           164     5.0%     3,404    11.1%   1,961    14.4%
  Imipramine           3,323    6.7%    718           38.9%          1,564   47.6%    424      1.4%    617      4.5%
  Paroxetine           1,535    3.1%    12            0.7%           45      1.4%     985      3.2%    493      3.6%
  Dosulepin            734      1.5%    5             0.3%           6       0.2%     490      1.6%    233      1.7%
  Escitalopram         472      1.0%    \<5           \<0.3%         \<5     \<0.3%   336      1.1%    133      1.0%
  Nortriptyline        420      0.8%    19            1.0%           20      0.6%     290      0.9%    91       0.7%
  Mirtazapine          404      0.8%    \<5           \<0.3%         6       0.2%     245      0.8%    151      1.1%
  Lofepramine          289      0.6%    \<5           \<0.3%         7       0.2%     216      0.7%    62       0.5%
  Venlafaxine          225      0.5%    \<5           \<0.3%         10      0.3%     133      0.4%    78       0.6%
  Trazodone            165      0.3%    \<5           \<0.3%         23      0.7%     79       0.3%    60       0.4%
  Fluvoxamine          61       0.1%    \<5           \<0.3%         \<5     \<0.3%   23       0.1%    31       0.2%
  Duloxetine           38       0.1%    \<5           \<0.3%         \<5     \<0.3%   28       0.1%    7        0.1%

**Abbreviations:** CYP, children and young people; SNRI, serotonin and norepinephrine reuptake inhibitor; SSRI, selective serotonin reuptake inhibitor; TCA, tricyclic and related antidepressant.

TCAs accounted for over 80% of first antidepressant prescriptions in 5- to 11-year-olds, and imipramine and amitriptyline were the most commonly first-prescribed individual drugs in this age group. In adolescents, two-thirds of the newly prescribed antidepressants were SSRIs. Over the whole study period, fluoxetine (38.3%) and amitriptyline (23.8%) were the most commonly first-prescribed individual drugs in 12- to 17-year-olds.

Incidence rates {#sec016}
---------------

Incidence rates for antidepressant prescribing showed distinct patterns in the age groups and were highest in 12- to 17-year-old females ([S1 Fig](#pmed.1003215.s005){ref-type="supplementary-material"}).

Antidepressant prescriptions decreased over the study period in 5- to 11-year-olds. For TCAs, incidence rates decreased by 92% from a peak of 1.6 per 1,000 person-years in males and by 86% from 0.9 in females in 1999 to less than 0.14 per 1,000 for both sexes in 2017 ([Fig 2](#pmed.1003215.g002){ref-type="fig"}). SSRI incidence rates, however, increased from 0.05 per 1,000 person-years in females and 0.06 in males in 1998 to 0.10 in females and 0.17 in males in 2017. Imipramine was initially the most commonly prescribed individual drug for 5- to 11-year-olds. These rates decreased and were similar to amitriptyline from 2003 in females and 2006 in males. Fluoxetine and sertraline incidence rates increased over the study period so that these 4 drugs had similar incidence rates in 2017 (0.04--0.07 per 1,000 person-years in females and 0.05--0.10 in males).

![Antidepressant drug class and individual drug incidence rates per 1,000 person-years in 5- to 11-year-olds, England, 1998--2017, by sex.\
SNRI, serotonin and norepinephrine reuptake inhibitor; SSRI, selective serotonin reuptake inhibitor; TCA, tricyclic and related antidepressant](pmed.1003215.g002){#pmed.1003215.g002}

For 12- to 17-year-olds, antidepressant incidence rates were 2.2 and 2.7 times higher in 2017 than 2005 in females and males, respectively ([S1 Fig](#pmed.1003215.s005){ref-type="supplementary-material"}). TCA incidence rates declined over the study period to 2.0 per 1,000 person-years in females and 0.7 in males in 2017 ([Fig 3](#pmed.1003215.g003){ref-type="fig"}). SSRI incidence rates increased between 1998 and 2002, decreased until 2005, and then increased again after this reaching a rate of 3.5 per 1,000 in males and 7.6 per 1,000 in females in 2017. The SSRI incidence rates per 1,000 person-years in 1998, 2002, and 2005 were 3.7, 7.1, and 2.5 in females and 1.1, 2.1, and 0.8 in males. Fluoxetine, sertraline, amitriptyline, and citalopram have been the 4 most commonly prescribed first antidepressants in 12- to 17-year-olds since 2003 in females and 2008 in males. This is due to a sharp decrease in paroxetine prescribing after 2002 and decreasing imipramine prescribing. The largest absolute increases were in fluoxetine and sertraline prescriptions in males and females, with sertraline becoming the second most commonly first-prescribed antidepressant for males in 2015 and for females in 2017.

![Antidepressant drug class and individual drug incidence rates per 1,000 person-years in 12- to 17-year-olds, England 1998--2017, by sex.\
SNRI, serotonin and norepinephrine reuptake inhibitor; SSRI, selective serotonin reuptake inhibitor; TCA, tricyclic and related antidepressant](pmed.1003215.g003){#pmed.1003215.g003}

[S2](#pmed.1003215.s006){ref-type="supplementary-material"}--[S4](#pmed.1003215.s008){ref-type="supplementary-material"} Figs show the crude antidepressant incidence rates over time for 12- to 17-year-olds by deprivation, region, and ethnicity. These rates were lower for those in the most deprived group ([S2 Fig](#pmed.1003215.s006){ref-type="supplementary-material"}) and in London than in other areas ([S3 Fig](#pmed.1003215.s007){ref-type="supplementary-material"}). White males and females had the highest crude incidence rates and Black and Asian groups the lowest ([S4 Fig](#pmed.1003215.s008){ref-type="supplementary-material"}).

IRRs {#sec017}
----

Fully adjusted IRRs for antidepressant prescribing are shown in [Table 3](#pmed.1003215.t003){ref-type="table"}. In 5- to 11-year-olds, the incidence decreased throughout the time period, with the largest decrease per year between 2002 and 2005. For 12- to 17-year-olds, there was an increase in incidence rates per year from 1998 until 2002, then a decrease until 2005, a small increase until 2008, and then another increasing trend per year similar in magnitude to the first period.

10.1371/journal.pmed.1003215.t003

###### IRRs for any antidepressant by age and sex fully adjusted for all variables shown and accounting for clustering by GP practice, England 1998--2017.
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                                            5--11 Years           12--17 Years                                                                                                                                        
  ----------------------------------------- --------------------- -------------- -------------- ------- -------------- -------------- --------- -------------- -------------- --------- -------------- -------------- ---------
  Trends within periods (per year)          1998--2002            0.92           (0.87--0.97)   0.001   0.87           (0.84--0.90)   \<0.001   1.10           (1.08--1.12)   \<0.001   1.08           (1.05--1.10)   \<0.001
  2002--2005                                0.78                  (0.73--0.84)   \<0.001        0.78    (0.74--0.82)   \<0.001        0.76      (0.74--0.77)   \<0.001        0.77      (0.74--0.79)   \<0.001        
  2005--2008                                0.92                  (0.85--0.98)   0.015          0.91    (0.86--0.96)   \<0.001        1.03      (1.01--1.05)   0.002          1.01      (0.98--1.04)   0.397          
  2008--2017                                0.97                  (0.95--1.00)   0.036          0.95    (0.94--0.97)   \<0.001        1.09      (1.08--1.09)   \<0.001        1.08      (1.08--1.09)   \<0.001        
  Townsend deprivation quintile             Q1 (least deprived)   1.00                                  1.00                                    1.00                                    1.00                          
  Q2                                        1.09                  (0.95--1.24)   0.226          0.96    (0.87--1.06)   0.432          1.15      (1.11--1.18)   \<0.001        1.14      (1.09--1.20)   \<0.001        
  Q3                                        1.09                  (0.95--1.26)   0.223          1.11    (1.00--1.23)   0.053          1.30      (1.26--1.35)   \<0.001        1.23      (1.17--1.30)   \<0.001        
  Q4                                        1.25                  (1.08--1.46)   0.004          1.18    (1.05--1.32)   0.005          1.46      (1.40--1.52)   \<0.001        1.37      (1.29--1.45)   \<0.001        
  Q5 (most deprived)                        1.33                  (1.11--1.59)   0.002          1.13    (0.98--1.30)   0.089          1.48      (1.41--1.55)   \<0.001        1.29      (1.20--1.39)   \<0.001        
  Not known                                 1.51                  (0.67--3.39)   0.315          1.27    (0.66--2.45)   0.480          1.12      (0.88--1.44)   0.349          1.18      (0.79--1.76)   0.428          
  Deprivation trend (excluding not known)   1.07                  (1.03--1.12)   0.001          1.05    (1.02--1.08)   0.002          1.12      (1.11--1.13)   \<0.001        1.08      (1.07--1.10)   \<0.001        
  Region                                    East Midlands         1.00                                  1.00                                    1.00                                    1.00                          
  East of England                           0.71                  (0.49--1.04)   0.077          0.77    (0.56--1.07)   0.116          1.18      (1.02--1.36)   0.027          1.12      (0.95--1.32)   0.191          
  London                                    0.50                  (0.37--0.69)   \<0.001        0.48    (0.37--0.63)   \<0.001        0.44      (0.39--0.49)   \<0.001        0.52      (0.45--0.60)   \<0.001        
  North East                                0.93                  (0.61--1.40)   0.716          0.86    (0.60--1.24)   0.422          0.76      (0.64--0.89)   0.001          0.75      (0.62--0.91)   0.004          
  North West                                0.74                  (0.54--1.01)   0.062          0.66    (0.50--0.87)   0.003          0.81      (0.72--0.91)   0.001          0.90      (0.78--1.04)   0.153          
  South East                                1.03                  (0.76--1.39)   0.861          1.08    (0.83--1.40)   0.570          1.20      (1.06--1.35)   0.003          1.29      (1.12--1.48)   \<0.001        
  South West                                0.87                  (0.63--1.22)   0.422          0.83    (0.62--1.11)   0.205          1.10      (0.96--1.25)   0.162          1.02      (0.87--1.19)   0.827          
  West Midlands                             0.80                  (0.57--1.11)   0.174          0.82    (0.62--1.09)   0.173          0.86      (0.76--0.98)   0.024          0.94      (0.81--1.09)   0.433          
  Yorkshire & Humber                        0.99                  (0.68--1.45)   0.971          0.98    (0.71--1.36)   0.913          0.81      (0.69--0.94)   0.006          0.77      (0.65--0.93)   0.006          
  Ethnic group                              White                 1.00                                  1.00                                    1.00                                    1.00                          
  Mixed                                     0.75                  (0.50--1.15)   0.187          0.85    (0.62--1.17)   0.319          0.66      (0.59--0.74)   \<0.001        0.81      (0.70--0.94)   0.007          
  Asian                                     0.70                  (0.54--0.89)   0.004          0.64    (0.52--0.78)   \<0.001        0.41      (0.38--0.44)   \<0.001        0.47      (0.42--0.52)   \<0.001        
  Black                                     0.71                  (0.51--0.98)   0.038          0.56    (0.42--0.75)   \<0.001        0.32      (0.29--0.36)   \<0.001        0.32      (0.27--0.38)   \<0.001        
  Chinese/Other                             0.49                  (0.26--0.91)   0.025          0.47    (0.28--0.79)   0.004          0.44      (0.38--0.51)   \<0.001        0.57      (0.47--0.69)   \<0.001        
  Not known                                 0.52                  (0.47--0.58)   \<0.001        0.54    (0.49--0.58)   \<0.001        0.45      (0.44--0.46)   \<0.001        0.41      (0.39--0.42)   \<0.001        

**Abbreviations:** CI, confidence interval; GP, general practitioner; IRR, incidence rate ratio.

Antidepressant incidence rates increased with increasing deprivation in all 4 age--sex subgroups after adjustment. The strongest trend was seen in 12- to 17-year-old females (adjusted IRR = 1.12, 95% confidence interval \[CI\] 1.11--1.13, p \< 0.001, per deprivation quintile increase). However, unadjusted estimates of antidepressant prescribing by deprivation showed a statistically significant trend of decreasing prescribing with increasing deprivation, driven by the most deprived quintile, in all age and sex groups apart from 5- to 11-year-old females ([S3 Table](#pmed.1003215.s004){ref-type="supplementary-material"}). For the older age group, adjusting for region resulted in increased prescribing rates with increasing deprivation, whereas adjusting for year alone did not affect the unadjusted trend results, and adjusting for just ethnicity attenuated the association but showed those living in more deprived areas were still less likely to be prescribed antidepressants. This statistically significant pattern with deprivation was also shown for 5- to 11-year-old females after adjusting for region. This association was only evident after taking GP practice clustering into account in the fully adjusted models ([Table 3](#pmed.1003215.t003){ref-type="table"}) in 5- to 11-year-old males. Within London, there was a statistically significant unadjusted association with deprivation and prescribing in 12- to 17-year-olds, with those living in more deprived areas having lower prescribing rates. After excluding London in the unadjusted analyses, increased prescribing with increasing deprivation was found for all groups apart from 5- to 11-year-old males, highlighting the influence of region on these results.

London had the lowest IRRs and the South East had the highest IRRs in all sex and age subgroups. The South East estimates were all more than double that of London. The North East had the second lowest prescribing rate estimates for 12- to 17-year-olds. These estimates were 1.4 (in males) and 1.7 (in females) times higher than the London estimates.

Asian, Black, and Chinese or other ethnic groups, as well as those whose ethnicity was not known, had statistically significantly lower prescription incidence rates compared with the White baseline group in 5- to 11-year-olds. For the older age group, the Mixed ethnic group also had significantly lower incidence rates than the White group. In both males and females, the lowest IRRs in adolescents were found in the Black group (IRR 0.32, 95% CI 0.27--0.38, p \< 0.001 and IRR 0.32, 95% CI 0.29--0.36, p \< 0.001, respectively) compared with the White group. Results were attenuated in the sensitivity analysis in which the not known ethnic group were recoded as White ([S2 Table](#pmed.1003215.s003){ref-type="supplementary-material"}). There were no statistically significant differences between all other ethnic groups and the White/not known baseline for females aged 5--11 years. In males aged 5--11 years in the Chinese or other (IRR 0.59, 95% CI 0.36--0.99, p = 0.046), Black (IRR 0.72, 95% CI 0.53--0.96, p = 0.027), and Asian (IRR 0.83, 95% CI 0.68--1.01, p = 0.067) ethnic groups, the IRRs were still lower than the White/not known group, although the Asian group was only borderline statistical significance. In the older age group, the attenuated results showed the same patterns, with only the male Mixed ethnic group no longer statistically significantly different from the baseline.

Prevalence rates {#sec018}
----------------

The prevalence rate patterns overall, in antidepressant drug classes, and in individual drugs were similar to the incidence rates ([S1](#pmed.1003215.s005){ref-type="supplementary-material"}, [S5](#pmed.1003215.s009){ref-type="supplementary-material"} and [S6](#pmed.1003215.s010){ref-type="supplementary-material"} Figs). Prevalence estimates for any antidepressant prescriptions were highest for 5- to 11-year-olds in 1999 and decreased over the study period. Despite a peak in the early 2000s in prescriptions for 12- to 17-year-olds, the highest rates for males and females were in 2017 (7.9 and 16.4 per 1,000 person-years, respectively). In 12- to 17-year-olds, there were an extra 6.6 females and 3.7 males per 1,000 person-years who had a second or later antidepressant prescription in 2017. There were very small differences between the incidence and prevalence rates in 5- to 11-year-olds throughout the study period.

[S7 Fig](#pmed.1003215.s011){ref-type="supplementary-material"} shows a negative association between spending per child on 'low-level' mental health services and the prescribing patterns from our study. There appears to be no strong correlation between either spending or prescribing and the depression and anxiety prevalence estimates.

Discussion {#sec019}
==========

Summary of main results {#sec020}
-----------------------

This study has shown a diverging pattern of decreasing prescribing of antidepressants in 5- to 11-year-olds between 1998 and 2017, whilst rates have more than doubled in 12- to 17-year-olds since 2005. The most commonly first-prescribed antidepressants are either licensed for use in CYP or included in national guidelines. Rates of antidepressant prescribing were higher for CYP living in more deprived areas after accounting for GP practice clustering and region. Children and adolescents living in South East England were more likely to be prescribed antidepressants, and those living in London the least likely. Prescribing rates were highest in White and lowest in Black adolescents.

Comparison with other studies {#sec021}
-----------------------------

This study has shown that the increase in antidepressant prescribing in CYP in England from 2005 previously found \[[@pmed.1003215.ref015]--[@pmed.1003215.ref019]\] has continued until 2017. The 2017 antidepressant prescribing prevalence rates in adolescents from our study (0.79% and 1.64%) are around half the associated depressive disorder estimates (1.6% and 3.8%) \[[@pmed.1003215.ref006]\] in males and females, respectively. Citalopram prescribing has previously been found to be higher than in our study---higher than fluoxetine in 6- to 18-year-olds \[[@pmed.1003215.ref016]\], similar to fluoxetine in under-18s in 2009 \[[@pmed.1003215.ref015]\], and the second most commonly prescribed antidepressant after fluoxetine in people aged under 20 \[[@pmed.1003215.ref020]\]. Whilst the inclusion of those aged 18 years \[[@pmed.1003215.ref016]\] and over \[[@pmed.1003215.ref020]\] who may have been treated as adults may explain the higher rates, other methodological differences, such as variation in factors not accounted for in the unadjusted analyses, could also be important.

A previous study reported that for people of all ages in England, the prevalence of antidepressant prescriptions was lowest in London and highest in the North East of England \[[@pmed.1003215.ref024]\]. We also found the lowest incident prescription rates in London; however, the North East was the next lowest area for adolescents. There could be differences in antidepressant prescribing patterns between CYP and adults, including initiating prescribing and the number of prescriptions because of the length of time people stay on antidepressants affecting the prevalence analysis, that account for this difference. Our study examined prescriptions, whilst Grigoroglou and colleagues \[[@pmed.1003215.ref024]\] used dispensing data, so differences in whether patients filled their prescriptions may also exist.

A report by the Children's Commissioner into early access to mental health support found variation in the stated spending on 'low-level' preventive and early-intervention (including nonspecialist psychological support services) services between different regions \[[@pmed.1003215.ref030]\]. London had the highest spending, and the East of England spent the least per child. We found that the lowest prescribing for adolescents was in London, which is located between the South East and East of England regions. These 2 areas had the highest prescribing IRR estimates for 12- to 17-year-olds. [S7 Fig](#pmed.1003215.s011){ref-type="supplementary-material"} shows there appears to be a negative association between spending per child on 'low-level' mental health services (London highest; East of England and South East lowest) and the prescribing patterns from our study (London lowest; East of England and South East highest). This implies that antidepressants might be prescribed more frequently to CYP in areas where there is less investment in preventive services or psychological support available, although further research is needed to test this hypothesis. That there was no strong correlation between either spending or prescribing and the depression and anxiety prevalence estimates could be due to differences in age groups and years studied.

Our study has good face validity because we found similar trends to those published elsewhere. For example, we found that after adjustment for GP practice clustering and region, CYP living in more deprived areas are more likely to receive antidepressant prescriptions compared with those in the less deprived areas, which has previously been shown for children and adolescents \[[@pmed.1003215.ref015],[@pmed.1003215.ref016]\] and adults \[[@pmed.1003215.ref024]\] in the UK. Although the unadjusted results showed lower antidepressant prescribing in adolescents living in the most deprived quintile ([S2 Fig](#pmed.1003215.s006){ref-type="supplementary-material"}), this was due to the lower prescribing and large proportion of people living in the most deprived quintile in London. Excluding London from an unadjusted analysis of trend over deprivation changed the estimates in 12- to 17-year-olds from 0.96 (p \< 0.001) in both sexes to 1.06 in females and 1.05 in males (both p \< 0.001) ([S3 Table](#pmed.1003215.s004){ref-type="supplementary-material"}). Measures of deprivation were not found to be statistically significantly associated with spending on CYP mental health per child at the Clinical Commissioning Group level in a study by Rocks and colleagues \[[@pmed.1003215.ref031]\]. This study included early help and targeted services (tier 2) and specialised Child and Adolescent Mental Health Services (CAMHS) (tier 3). Spending on early interventions by nonspecialists (tier 1) could influence antidepressant prescriptions and might be linked to deprivation.

Strengths and limitations {#sec022}
-------------------------

The main strengths of this study are its size, representativeness, and duration. We analysed data from over 4.3 million CYP across England over a 20-year period, which, to our knowledge, is the largest study to date on antidepressant prescribing in CYP. The vast majority of the UK population are registered with a GP practice \[[@pmed.1003215.ref013]\], and the QResearch database is the most nationally representative primary care database in England \[[@pmed.1003215.ref032]\] with comprehensive information on prescriptions. This means that the results are likely to generalise well within the UK. We have been able to examine a long time series for different sex and age groups and investigate variation by deprivation, region, and ethnicity whilst taking all these factors into account.

A limitation of the study is that it does not include any secondary care prescriptions. There is no publicly available information about antidepressant prescribing for CYP in secondary care in the UK. Most parents would initially first visit a GP with concerns about their child's mental health issues \[[@pmed.1003215.ref033]\]. The GP would refer them to a specialist in child and mental health following if appropriate \[[@pmed.1003215.ref005],[@pmed.1003215.ref010]\]. Furthermore, in the UK, GPs are typically responsible for the ongoing prescribing of antidepressant medicines if initiated by a specialist. It is possible that what we have identified as a first prescription is actually a subsequent prescription in primary care following an initial prescription in secondary care. Without secondary care prescriptions, the prevalence estimates will be underestimates of the total antidepressant prescriptions in CYP. However, the prevalence patterns should be unaffected by who initiated the first prescription if prescribing is transferred to primary care. We were only able to assess whether antidepressants were prescribed, not whether they were dispensed or taken. Unmeasured confounding may also still be present. We chose to include all CYP regardless of whether they had an appropriate indication recorded and cannot be sure that particular antidepressants were prescribed for the indications they are licensed for.

Because we used data routinely recorded in primary care rather than prospectively collecting the data specifically for the study, not all information we required was available. Despite using all available ethnicity information from QResearch and HES records, ethnicity was still missing for 40%. As a sensitivity analysis, we recoded those with no ethnicity information to a new White/not known group. This attenuated the results for the other ethnic groups, but these were still statistically significant for females aged 12--17 years, males aged 12--17 years (apart from the Mixed group), and Black and Chinese or other ethnic groups in males aged 5--11 years.

Implications {#sec023}
------------

Our study was not designed to determine whether increased prescribing of antidepressants in CYP since 2005 is due to increasing rates of mental health problems, greater awareness and help-seeking for those with mental health issues, prescribing behaviour, patient choice, or because there are issues with accessing other psychological therapies \[[@pmed.1003215.ref006]\]. Generally, the antidepressants prescribed to CYP appear to be those licensed for use in under-18s in the UK or listed for use with particular indications in the British National Formulary for Children \[[@pmed.1003215.ref008]\] despite not being licensed. The rapid recent increase of sertraline as the first antidepressant prescribed is of interest. Sertraline is licensed in the UK for use in CYP for obsessive-compulsive disorder and recommended as a second-line treatment for major depression in CYP by NICE \[[@pmed.1003215.ref005]\]. The prevalence of obsessive-compulsive disorder is low in England (0.4% in 2017) \[[@pmed.1003215.ref006]\], and as a second-line drug, sertraline would not be expected to be the first antidepressant prescribed for major depression. There are currently no UK guidelines on treating CYP with anxiety, although meta-analyses have shown SSRIs, including sertraline, to be effective \[[@pmed.1003215.ref034]\]. General practitioners may be following the adult guidance, which suggests sertraline and was published in 2011 \[[@pmed.1003215.ref035]\], after which female adolescent sertraline prescription rates rapidly increased. The relatively high prescribing rates of amitriptyline should be explored further to determine what indications this drug is being prescribed for. Whilst amitriptyline is unlicensed for use in CYP, it is included in NICE guidelines for treating headaches \[[@pmed.1003215.ref012]\] and the British National Formulary for Children for treating neuropathic pain \[[@pmed.1003215.ref008]\]. TCAs in general are not recommended for depressive disorder in CYP and those who self-harm \[[@pmed.1003215.ref036]\] because of life-threatening cardiac risks associated with overdose, but rates of self-harm have been shown to be increasing in 13- to 16-year-olds in recent years in the UK \[[@pmed.1003215.ref037]\]. Understanding which indications are recorded around the time of these first antidepressant prescriptions is important, and work examining this has been analysed separately \[[@pmed.1003215.ref014]\].

Future work should further examine whether any barriers in awareness, access to appropriate healthcare services, and treatment exist, and if so, whether they vary for different groups and how they can be tackled. Determining whether increased spending on preventive, early-intervention services and access to psychological therapies leads to lower antidepressant prescription rates, and how these services compare in terms of outcomes is an important area of work that could lead to possible savings in healthcare spending and improved health for the population.

Supporting information {#sec024}
======================
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###### Antidepressant group incidence rates and 95% CIs per 1,000 person-years in 12- to 17-year-olds, England 1998--2017, by Townsend deprivation quintile (excluding not known) and sex.

CI, confidence interval; Townsend Q1, least deprived quintile; Townsend Q5, most deprived quintile
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Comments from the reviewers:

\*\*\* Reviewer \#1:

I found this to be an interesting and well written article. The topic is of considerable public health importance and of wider societal concern, for the UK and for many other countries. The data source utilised is robust and the study design and statistical analyses seem appropriate. I have just a few minor critical comments, which are listed below.

1\) It would be preferable to include at least one implication (for clinicians, public health experts, policymakers or researchers) in the \'Conclusions\' subsection of the abstract.

2\) The authors ought to say more about the risks associated with prescribing of amitriptyline and other tricyclic antidepressants given that: a) the drug is highly toxic in overdose, and the National Institute for Health and Care Excellence (NICE) recommended in November 2011 that the drug should not be prescribed to anyone with a history of self-harm (NICE, Clinical Guideline no. 133); b) incidence of self-harm has risen sharply among 13-16 year olds in the UK from 2011 (Morgan et al. BMJ 2017;359:j4351).

3\) In the Covariates subsection of the Methods, the authors make brief mention of missing data as regards the ethnicity variable that was available in the QResearch dataset. Further on in the manuscript, in the \'Strengths and limitations\' subsection of the Discussion, information is given concerning the amount of data that are missing for this variable. It would be ideal if this more detailed information was provided in the Methods. Likewise, for any tables that report information pertaining to ethnicity, it would be useful for readers to be informed about the level of missing data for this variable via footnotes.

4\) Given that they are geographically adjacent, it is an intriguing finding that the lowest prescription incidence rate observed was for London and the highest was for the South East. Many readers will likely be unaware that these two regions both lie in the South East of England, and so I suggest that this is explained.

\*\*\* Reviewer \#2:

This is a pharmacoepidemiological study, using a general practice database in the UK (QResearch) to examine prevalence, incidence and associated temporal trends in antidepressant prescribing for 5-17 year olds.

A strength of the paper is its topical nature: data are available up to 2017. It has a large sample size and the sample is believed to be representative. While the analysis does not assess duration of therapy, it provides some relevant information on this topic since both incidence and prevalence estimates are presented. The trends over time are complex, and this is addressed with a piecewise regression approach in the multivariable component of the analysis.

The study is highly descriptive. Information on the reasons for prescribing are apparently not available, so the results (as the authors point out) are subject to various interpretations (e.g. see the non-specific interpretive statement at the start of the \"implications\" section. Nevertheless, it is important to understand patterns of drug use, and associated trends, even if this mainly generates hypotheses for additional studies. In addition to describing trends, model-based estimates are presented, which produce some interesting results.

The main findings are that there are differing trends in the 5-11 (decreasing) versus the 12-17 (increasing) age groups, and that the most commonly prescribed medications are those recommended by guidelines.

Another important finding is that the increase in antidepressants use in the 12-17 year olds has been substantial (a 2-3 fold increase between 2005 and 2017), which is important to know. Unfortunately, it is difficult to interpret since the absolute rates remain low, so the increase may either be a good or a bad thing. This is another example of where the study generates interesting hypotheses that should be address by additional research. Lower incidence in ethnic groups (Black and Asian) point towards possible issues of stigma and/or literacy in these groups.

Unadjusted estimates showed decreased prescribing in areas with increased deprivation whereas the opposite trend is seen in the adjusted analysis. Obviously some form of confounding (due to more ethnic minorities living in the most deprived areas?) is occurring but since the authors report only omnibus adjustments for multiple factors, it is not possible for readers to identify the source of this confounding.

The authors make some interesting \"ecological\" comparisons, which leads to the generation of additional hypotheses. For, example, the possibility that low access to basic mental health care in regions that spend little on \"low level\" care, may lead to higher incidence of antidepressant use.

The incidence data is described as \"first\" use of an antidepressant, but the data collection appears to go only 12 months prior to cohort entry for some patients, so the study appears not to confirm first use.

In Table 3, the (trends within periods) rows doesn\'t seem to have a baseline group, so I\'m not sure how to interpret the reported IRRs.

Overall, I feel that this is a good descriptive study that provides important information.

\*\*\* Reviewer \#3:

Comments on ms PMEDICINE-D-20-00542

\"Trends and variations in the incidence and prevalence of antidepressant prescribing in children and young people in England: a population-based cohort study

This article provides information about antidepressant prescription in the age group 5-17 yrs in England. The data source is a primary care database containing anonymised healthcare records from primary care, with an incidence cohort of 4.3 million children and young people.

Some comments:

The size of the database is impressive; however, I do not fully understand the degree to what this database covers the population of interest, i.e. children and adolescents \<18 yrs of age with mental health problems/depression. The authors acknowledge that they do not have access to data from the specialist level mental health services, but could they describe how the health care system in the UK is organized? Where would a family turn to seek help for a depressed youth? How likely is it that your first visit would be in primary care? In many other countries, pharmacological treatment of depressed youth would be the sole responsibility of the specialist level services, and primary care would refer youth in need of pharmacological treatment to the specialist services. Is this different in the UK?

Without this information, it is impossible to assess the relevance of the results, both in regard to how generalizable they are to the entire UK population but also to other contexts outside the UK. A related question is if the geographical variation seen in the results could be explained by access to specialist level services (e.g. is that more accessible in the London area than in other parts of the UK)?

I ran across an article on the UK primary care database (Moore ea, BMJ 2009) that may be of relevance.

The authors have added a reference in the introduction that shows that the waitlist to see a mental health specialist was long in 2017. How would a \"long wait-list condition\" affect patterns of seeking help? Would it be likely that youth instead contacted primary care, or would it lead to a delay in treatment?

In this regard, please explain what \"low-level services\" mean and, if possible, how the organisation of the service system may have influenced the results (or how we can understand them). Does a \"low-level service\" provide only psychosocial interventions, or do they also prescribe meds? Would they refer a youth in need of meds to some other health care level, and if so, which one? The authors state (line 327-328) that the absence of psychosocial support could lead to an increased prescribing of antidepressants. It could actually be the other way around; with increased access to psychosocial counselling, more youth would meet someone who could identify the need for pharmacological treatment.

Given the unclarity of the extent to which the included cohort represents the general population, think the title may be misleading. It is stated that this is a \"population-based cohort study\" - but if only part of the population is included in the study that must be clearly stated.

The paper would improve by including perspectives from other countries in Europe and elsewhere, e.g Abbin-Karahagopian, Herta ea (2014, Eur J Clin Pharmacol), Noordam ea (2015, Eur J Clin Pharmacol), Lagerberg ea (2018, J European J of Child and Adolescent Psychiatry).

The stated aims were to describe trends, estimate variation in uptake, and assess to what extent the NICE guidelines were adhered to. I am not sure what \"variation in uptake\" actually means in this study, especially not knowing to what extent this database covers the entire population.

Please explain the term \"Townsend deprivation quintiles\".

\*\*\* Reviewer \#4:

This is an interesting and useful study on the trends and variation in the incidence and prevalence of antidepressant prescribing in children and young people in England. The study design, datasets, statistical methods and analyses, and presentation (tables ang figures) and interpretation of the results are mostly adequate. However, there are still a few important issues needing attention.

1\) Strictly speaking, it\'s a cohort study. As it\'s not about incidence/prevalence in the population, it\'s better not to use \'population-based\' in case mis-understanding and mis-interpretation.

2\) In the conclusion of the abstract, it says \'the trends and variation in antidepressant prescribing found may reflect true differences in need and risk factors, access to diagnosis and services, prescribing behaviour, or young people\'s help-seeking behaviour\'. However, apart from analyses of trends in incidence and prevalence of antidepressant prescriptions over time, there are no data or formal analyses on all those explanatory factors listed in the conclusion such as risk factors, access to services, prescribing behaviours and etc. It\'s good that the authors have done a nice job on the trends of prescription of antidepressant, but in the term of comprehensively explaining the trends, it seems a bit lacking solid evidence and analyses. Can authors find out the data within the cohorts on underlying conditions/co-morbidities, and their severity, related hospital care, and other risk factors, and carry out analyses to show the trends so that can offer some explanations on trends of prescriptions?

3\) Figure 2 and 3 are useful. However, are they adjusted incidence rates? If not, can we see the adjusted incidence rates in one way or another (comprehensively adjusted for everything)?

4\) Table 3 on IRRs are mostly fine. However, when talking about fully adjusted IRRs, it became a bit limited as only adjusted for age, sex, deprivation, region, and ethnicity which are mostly demographics. The other important factors such as diagnosis, case-mix, hospital care, and other risk factor are not adjusted. If the data are not available, then at least should address this carefully in the limitations.

\*\*\*

Any attachments provided with reviews can be seen via the following link:

\[LINK\]

10.1371/journal.pmed.1003215.r003
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3 Jun 2020

Dear Dr. Jack,

Thank you very much for re-submitting your manuscript \"Incidence and prevalence of primary care antidepressant prescribing in children and young people in England, 1998-2017: a population-based cohort study\" (PMEDICINE-D-20-00542R2) for consideration at PLOS Medicine.

I have discussed the paper with editorial colleagues and it was also seen again by three reviewers. I am pleased to tell you that, provided the remaining editorial and production issues are dealt with, we expect to be able to accept the paper for publication in the journal.

The remaining issues that need to be addressed are listed at the end of this email. Any accompanying reviewer attachments can be seen via the link below. Please take these into account before resubmitting your manuscript:

\[LINK\]

Our publications team (<plosmedicine@plos.org>) will be in touch shortly about the production requirements for your paper, and the link and deadline for resubmission. DO NOT RESUBMIT BEFORE YOU\'VE RECEIVED THE PRODUCTION REQUIREMENTS.

\*\*\*Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.\*\*\*

In revising the manuscript for further consideration here, please ensure you address the specific points made by each reviewer and the editors. In your rebuttal letter you should indicate your response to the reviewers\' and editors\' comments and the changes you have made in the manuscript. Please submit a clean version of the paper as the main article file. A version with changes marked must also be uploaded as a marked up manuscript file.

Please also check the guidelines for revised papers at <http://journals.plos.org/plosmedicine/s/revising-your-manuscript> for any that apply to your paper. If you haven\'t already, we ask that you provide a short, non-technical Author Summary of your research to make findings accessible to a wide audience that includes both scientists and non-scientists. The Author Summary should immediately follow the Abstract in your revised manuscript. This text is subject to editorial change and should be distinct from the scientific abstract.

We hope to receive your revised manuscript within 1 week. Please email us (<plosmedicine@plos.org>) if you have any questions or concerns.

We ask every co-author listed on the manuscript to fill in a contributing author statement. If any of the co-authors have not filled in the statement, we will remind them to do so when the paper is revised. If all statements are not completed in a timely fashion this could hold up the re-review process. Should there be a problem getting one of your co-authors to fill in a statement we will be in contact. YOU MUST NOT ADD OR REMOVE AUTHORS UNLESS YOU HAVE ALERTED THE EDITOR HANDLING THE MANUSCRIPT TO THE CHANGE AND THEY SPECIFICALLY HAVE AGREED TO IT.

Please ensure that the paper adheres to the PLOS Data Availability Policy (see <http://journals.plos.org/plosmedicine/s/data-availability>), which requires that all data underlying the study\'s findings be provided in a repository or as Supporting Information. For data residing with a third party, authors are required to provide instructions with contact information for obtaining the data. PLOS journals do not allow statements supported by \"data not shown\" or \"unpublished results.\" For such statements, authors must provide supporting data or cite public sources that include it.

Please let me know if you have any questions. Otherwise, we look forward to receiving the revised manuscript shortly.

Sincerely,

Richard Turner, PhD

Senior Editor, PLOS Medicine

<rturner@plos.org>

\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\--

Requests from Editors:

In your data statement (in the submission form, to appear in the article metadata upon publication) we suggest substituting the following point of access: <https://www.qresearch.org/information/information-for-researchers/>.

We suggest quoting 1-2 additional quantitative findings in your abstract - for example, the finding quoted at line 329 would seem of interest.

Also, we would suggest adding a sentence, say, to the abstract to quote quantitative observations on the classes of antidepressants prescribed.

Please adapt the abstract so that 95% CI are quoted along with incidence rate ratios and p values.

In the sentence addressing study limitations at the end of the \"methods and findings\" subsection of your abstract, please quote one further limitation - possibilities could be that antidepressant use has not been measured, and the issue of unmeasured confounding. We would also suggest including these issues in the element of the discussion section summarizing study limitations.

You mention that the study protocol has been published (line 173). Please highlight analyses that were not prespecified.

Please refer to the attached STROBE checklist in your methods section (e.g., \"See S1_STROBE\").

Please move the ethics statement from the end of the ms to the methods section.

Noting instances of \"p\<0.0001\" in the tables, please quote exact p values or \"p\<0.001\" throughout, unless there are specific statistical reasons to do otherwise.

Please remove the information on funding, competing interests and data availability from the end of the ms - this information will appear in the article metadata (via the submission form).

Please make that \"PLoS ONE\" in the reference list

Comments from Reviewers:

\*\*\* Reviewer \#1:

The authors have adequately addressed all of my comments.

\*\*\* Reviewer \#3:

Comments on ms PMEDICINE-D-20-00542R2

\"Trends and variations in the incidence and prevalence of antidepressant prescribing in children and young people in England: a population-based cohort study

The manuscript has been improved in several ways.

The authors provide more information on the clinical practice in England with regard to CYP with mental health problems.

They have also provided more information on the QResearch database and how they have tried to link the results to other data (i.e. the Townsend deprivation index).

The strength of this study is the size of the cohort and the long time period studied (which the authors themselves have identified, line 455-466). The identified trends are similar to what is seen in many other countries. The authors also do a good job in trying to relate their findings to other data of interest (demographic variations etc).

Since the aim is primarily descriptive, it is a weakness (also identified) that there is no data provided on what is prescribed from the specialist level, and lack of information on diagnoses/indications. It is stated that \"In the UK, prescribing antidepressants to CYP should only be done after assessment and diagnosis by a child and adolescent psychiatrist or other expertise in child and adolescent mental health\". To me, this seems as a quite strong recommendation and most likely, the results would be affected if specialist level data was provided alongside what is prescribed within on primary care level.

I agree with reviewer \#4 that this is should be viewed as a cohort study; it could actually strengthen the argumentation. The authors provide support for the use of the QResearch database, and its representativity of the entire population. I accept that - but still we can assume that a lot of information on the issue in focus - prescription of antidepressants to CYP- are not included in this dataset.

Given that the recommendation is that antidepressants should be described by specialists, the authors may claim that they with this impressive data set can show that this is not the case. They do have strong evidence that there is a large number of prescriptions of antidepressants being done within the primary care health services, with regional and other variations. Given that the specialist mental health services should be responsible for prescription of antidepressants one would assume that there should be very little (or no) prescriptions, or that the prescription patterns within primary care should be affected by change in policy or access to mental health services. The last question is also what the authors have tried to study when comparing regional variations in prescribing with other data on mental health resources.

One aim of the study was to assess to what extent the NICE guidelines for CYP are being adhered to. Is it possible to claim that based on these findings, guidelines are generally adhered to with regard to which antidepressants are prescribed, but not the way in which they are prescribed? I understand that GPs many times may need to deal with problems that \"should\" be handled on the specialist level, and that this pragmatic way of taking care of a medical problem may work out just fine and may be better than doing nothing. Still, these data provide a matrix for discussing the strengths and weaknesses in how youth get access to care.

I think the study has its merits, but primarily in the sense described above. It does not give a full picture of prescription patterns in England but rather a full picture of prescription patterns within primary care in England. The title should be adjusted accordingly.

\*\*\* Reviewer \#4:

I am satisfied with the authors\' response. No further issues needing attention.

\*\*\*

Any attachments provided with reviews can be seen via the following link:

\[LINK\]

10.1371/journal.pmed.1003215.r005
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23 Jun 2020

Dear Dr Jack,

On behalf of my colleagues and the academic editor, Dr. Clara Hellner, I am delighted to inform you that your manuscript entitled \"Incidence and prevalence of primary care antidepressant prescribing in children and young people in England, 1998-2017: a population-based cohort study\" (PMEDICINE-D-20-00542R3) has been accepted for publication in PLOS Medicine.

PRODUCTION PROCESS

Before publication you will see the copyedited word document (in around 1-2 weeks from now) and a PDF galley proof shortly after that. The copyeditor will be in touch shortly before sending you the copyedited Word document. We will make some revisions at the copyediting stage to conform to our general style, and for clarification. When you receive this version you should check and revise it very carefully, including figures, tables, references, and supporting information, because corrections at the next stage (proofs) will be strictly limited to (1) errors in author names or affiliations, (2) errors of scientific fact that would cause misunderstandings to readers, and (3) printer\'s (introduced) errors.

If you are likely to be away when either this document or the proof is sent, please ensure we have contact information of a second person, as we will need you to respond quickly at each point.

PRESS

A selection of our articles each week are press released by the journal. You will be contacted nearer the time if we are press releasing your article in order to approve the content and check the contact information for journalists is correct. If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximize its impact.

PROFILE INFORMATION

Now that your manuscript has been accepted, please log into EM and update your profile. Go to <https://www.editorialmanager.com/pmedicine>, log in, and click on the \"Update My Information\" link at the top of the page. Please update your user information to ensure an efficient production and billing process.

Thank you again for submitting the manuscript to PLOS Medicine. We look forward to publishing it.

Best wishes,

Richard Turner, PhD

Senior Editor

PLOS Medicine

[plosmedicine.org](http://plosmedicine.org)

[^1]: I have read the journal\'s policy and the authors of this manuscript have the following competing interests: CC has received a research grant from Nottingham BRC. RDK is a member of the Advisory Council on the Misuse of Drugs and Guideline Committee member, NICE Clinical Guideline on Chronic Pain. AC has received research and consultancy fees from INCiPiT (Italian Network for Paediatric Trials), CARIPLO Foundation, and Angelini Pharma. JHC is professor of clinical epidemiology and general practice at the University of Oxford and co-director of QResearch, a not-for-profit organisation that is a joint partnership between the University of Oxford and Egton Medical Information Systems (the leading commercial supplier of IT for 60% of general practices in the UK). JHC was also a paid director of ClinRisk Ltd, which produces open- and closed-source software to ensure the reliable and updatable implementation of clinical risk equations within clinical computer systems to help improve patient care.
